首页 阿卡迪亚(usACAD)-基本信息

阿卡迪亚(usACAD)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:21.32

最高价:21.4

成交量:4774795.0

昨收价:21.2

最低价:20.84

最新价:21.15

行情图标
概要信息

中文名称:阿卡迪亚


英文名称:ACADIA Pharmaceuticals


行业:医疗


简介:Acadia Pharmaceuticals Inc.于1993年在佛蒙特州成立,是一家生物制药公司,专注于创新型微分子药物的研发和商业化,以解决在神经系统和中枢神经系统疾病上未满足的医疗需求


电话:1-858-5582871


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

ACADIA Pharmaceuticals Inc.专注于开发及商品化未满足医疗需求的神经及相关中枢神经系统疾病的小分子药物。阿卡迪亚制药公司领先的候选产品NUPLAZID已完成治疗帕金森氏症精神病的III期临床试验;进入阿兹海默症精神病的II期临床研究;已完成治疗精神分裂症的II期临床试验。阿卡迪亚制药公司其他候选产品包括: Pimavanserin——用于帕金森氏症等疾病的治疗,目前处于IV阶段; AGN XX/YY——用于治疗慢性疼痛,目前处于II期临床试验阶段; AC-262271——用于治疗青光眼,与Allergan合作开发; AM-831——用于治疗精神分裂,与明治株式会社(Meiji Seika Kaisha)合作开发。ACADIA Pharmaceuticals公司与Allergan, Inc.合作慢性疼痛和青光眼的临床阶段计划。

交易日期 交易人 职位 类型 交易份额 价格
2019-06-05 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Buy 31229 --
2019-06-05 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Sell 421756 --
2019-06-05 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Buy 31229 --
2019-01-08 Brege (Laura A) Director Sell 10000 20.00
2019-01-08 Brege (Laura A) Director Buy 10000 2.16
2018-11-29 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Buy 11178823 17.00
2018-11-29 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Sell 489977 --
2018-11-29 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Buy 71647 --
2018-11-29 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Buy 585882 17.00
2018-11-29 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Buy 71647 --
2018-09-19 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Buy 38207 19.01
2018-09-19 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Buy 131007 19.09
2018-09-19 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Buy 920495 18.64
2018-09-19 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Buy 4245 19.01
2018-09-19 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Buy 14555 19.09
2018-09-19 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Buy 102267 18.64
2018-03-01 Soland (Daniel B) Director Buy 3000 22.52
2018-02-28 Soland (Daniel B) Director Buy 3000 24.09
2018-02-28 Soland (Daniel B) Director Buy 2000 23.02
2018-02-28 Soland (Daniel B) Director Buy 2000 24.52
2018-01-28 Baity (Glenn F) General Counsel Sell 36558 32.39
2018-01-09 Baity (Glenn F) General Counsel Buy 50179 2.18
2018-01-01 Brege (Laura A) Director Buy 15000 8.06
2018-01-01 Baity (Glenn F) General Counsel Buy 74321 2.18
2018-01-01 Baity (Glenn F) General Counsel Sell 74321 30.14

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Citadel Advisors Llc 1776340 1.23% -1062582 -37.43% 2019-03-31
BlackRock Fund Advisors 5904916 4.09% 26372 0.45% 2019-07-31
T. Rowe Price Associates, Inc. 7357656 5.10% 501519 7.31% 2019-03-31
Vanguard Group Inc 9497642 6.59% -644022 -6.35% 2019-03-31
BlackRock Inc 10718708 7.43% 585242 5.78% 2019-03-31
Fidelity Management & Research Company 13472564 9.32% -248798 -1.81% 2019-07-31
Fidelity Management and Research Company 21568857 14.96% 38464 0.18% 2019-03-31
FMR Inc 21582357 14.97% 38464 0.18% 2019-03-31
Baker Bros Advisors LP 39713842 27.55% -- -- 2019-03-31
Fidelity Management Trust Co 5690355 3.94% -- -- 2019-07-31
State Street Corporation 4865697 3.38% 26511 0.55% 2019-03-31
First Trust Advisors L.P. 4815776 3.34% 677051 16.36% 2019-03-31
Goldman Sachs Group Inc 1933145 1.34% -418767 -17.81% 2019-03-31
Great Point Partners LLC 2000000 1.39% -752256 -27.33% 2019-03-31
Northern Trust Investments Inc 2240856 1.55% 23377 1.05% 2019-07-31
SSGA Funds Management Inc 2403648 1.66% 28969 1.22% 2019-07-31
Invesco Ltd (OFI / OppenheimerFunds) 2568618 1.78% -2569 -0.10% 2019-07-31
Vanguard Investments Australia Ltd 2842823 1.97% 433 0.02% 2019-07-31
OppenheimerFunds Inc 3644406 2.53% 15830 0.44% 2019-03-31
Fidelity SelectCo, LLC 3814974 2.64% -- -- 2019-07-31
Deutsche Bank AG 2010567 1.39% 162679 8.80% 2018-12-31
BlackRock Asset Management Canada Ltd 2642492 1.83% -456 -0.02% 2019-05-31
Geode Capital Management, LLC 2489878 1.73% 1422640 133.30% 2018-12-31
HHG PLC 3142042 2.18% -742 -0.02% 2018-12-31
Deutsche Asset Management Investment GmbH 5073144 3.52% 3795870 297.19% 2019-05-31
OFI Global Asset Management, Inc. 2567019 1.78% -342289 -11.77% 2019-04-30
Janus Capital Management LLC 2671040 1.86% -2837257 -51.51% 2019-03-31
Point72 Asset Management, L.P. 2246600 1.56% 439600 24.33% 2018-12-31
Capital Research and Management Company 2587000 2.07% -2546000 -49.60% 2018-11-30
BlackRock Institutional Trust Company NA 2885640 2.31% 167772 6.17% 2018-06-30
Orbimed Advisors, LLC 4282400 3.42% 941700 28.19% 2018-06-30
State Street Corp 5826875 4.66% 1651126 39.54% 2018-06-30
Close Finsbury Asset Management Limited 1640000 1.31% -- -- 2018-05-31
Northern Trust Investments N A 1269645 1.02% 779741 159.16% 2018-06-30
Palo Alto Investors, LLC 1650780 1.32% -- -- 2018-06-30
Deutsche Asset & Wealth Management Investment GmbH 1300167 1.02% 507 0.04% 2018-09-12
Deutsche Asset Mgmt Invst Gesenschaft 1262209 1.01% 245000 24.09% 2018-06-30
Capital World Investors 1057000 0.85% -4076000 -79.41% 2018-06-30
Columbia Mangmt Investment Advisers, LLC 699953 0.56% -52423 -6.97% 2018-03-31
Pictet Asset Management SA 701833 0.56% -719027 -50.61% 2018-03-31
Franklin Advisers Inc 2166346 1.74% -1071500 -33.09% 2018-03-31
J.P. Morgan Investment Management Inc 1287112 1.03% -14546 -1.12% 2018-03-31
UBS Group AG 710488 0.57% -26853 -3.64% 2018-01-31
Healthcor Management LP 1378000 1.10% 1378000 -- 2018-03-31
Fred Alger Management Inc 1367683 1.10% -798346 -36.86% 2018-03-31
NORGES BANK 800491 0.64% -92393 -10.35% 2017-12-31
Invesco Advisers, Inc 1690971 1.36% -229281 -11.94% 2017-12-31
Waddell & Reed Investment Management Co 2881692 2.32% -184572 -6.02% 2017-12-31
Sectoral Asset Management Inc 1131722 0.91% 309330 37.61% 2017-12-31
Goldman Sachs Asset Management LP 1436985 1.17% -116230 -7.48% 2017-09-30
Senator Investment Group LP 1443738 1.18% -556262 -27.81% 2017-09-30
Eagle Asset Management, Inc. 979303 0.81% 24276 2.54% 2016-09-30
Lord, Abbett & Co LLC 1165284 0.96% -1026169 -46.83% 2016-09-30
BlackRock, Inc. 5581281 2.00% 190935623 0.10% 1999-11-30
FMR LLC 14965545 2.00% 511971294 0.20% 1999-11-30
Stephen Biggar, Ph.D., M.D. 20518317 2.00% 701931625 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
T. Rowe Price QM US Small-Cap Gr Eq Fd 769900 0.53% 59900 8.44% 2019-06-30
Fidelity Growth Company Commingled Pool 5678280 3.93% -- -- 2019-06-30
First Trust NYSE Arca Biotech Fund 3703775 2.56% -8925 -0.24% 2019-07-31
Vanguard Total Stock Market Index Fund 2818470 1.95% 574 0.02% 2019-06-30
T. Rowe Price Health Sciences Fund 2653130 1.84% 47000 1.80% 2019-06-30
Vanguard Small Cap Index 2576456 1.78% -46372 -1.77% 2019-06-30
T. Rowe Price New Horizons Fund 2570716 1.78% 38600 1.52% 2019-06-30
iShares Russell 2000 ETF 2317336 1.60% 23220 1.01% 2019-07-30
SPDR 2289544 1.58% 35595 1.58% 2019-07-31
Invesco Oppenheimer Global Fund 1961139 1.36% -- -- 2019-06-30
Fidelity 860504 0.60% -- -- 2019-05-31
Fidelity Advisor 890486 0.62% -- -- 2019-06-30
iShares Russell 2000 Growth ETF 966663 0.67% 12405 1.30% 2019-07-30
iShares Nasdaq Biotechnology ETF 1423148 0.98% 15519 1.10% 2019-07-30
Vanguard Small Cap Growth Index Fund 1478746 1.02% -8010 -0.54% 2019-06-30
Vanguard Extended Market Index Fund 1558732 1.08% -908 -0.06% 2019-06-30
DWS Verm 760809 0.53% -- -- 2019-04-30
iShares US Small Cap ETF (CAD-Hedged) 2314430 1.61% -3888 -0.17% 2019-05-30
DWS Biotech 1946208 1.35% 1459445 299.83% 2019-04-30
Vanguard Small Cap Index Fund 2624208 1.82% 16892 0.65% 2019-04-30
Oppenheimer Global Fund 1961139 1.36% -- -- 2019-03-31
Janus Henderson Enterprise Fund 2501075 1.74% 1674 0.07% 2018-12-31
Goldman Sachs Small/Mid Cap Growth Fund 789274 0.55% 219668 38.56% 2018-12-31
HBM Healthcare Investments AG 700000 0.49% -- -- 2018-12-31
BlackRock Health Sciences Opps Port 655400 0.52% -- -- 2018-11-30
Janus Henderson Triton Fund 1760332 1.41% 186453 11.85% 2018-03-31
American Funds Growth Fund of Amer 1260000 1.01% -- -- 2018-03-31
VA CollegeAmerica SMALLCAP Wld Fd 1057000 0.85% -2546000 -70.66% 2018-06-30
Franklin Biotechnology Discovery Fund 970200 0.78% -46800 -4.60% 2018-03-31
AZ InvestEd Ivy Mid Cap Growth Fund 935527 0.75% -99940 -9.65% 2017-12-31
American Funds SMALLCAP World Fund 1057000 0.85% -2546000 -70.66% 2018-06-30
State Street Russell Small/Mid Cap Idx Fd Cl I 318043 0.26% 3400 1.08% 2017-06-30
First Trust NYSE Arca Biotech ETF 4411944 3.42% -- -- 2018-09-13
Janus Enterprise D 2499401 2.00% -- -- 2018-06-30
Vanguard Total Stock Mkt Idx 2504889 2.00% 2576 0.10% 2018-07-31
Oppenheimer Global A 2350189 1.88% -- -- 2018-07-31
Vanguard Small Cap Growth Index Inv 1437536 1.15% 24886 1.76% 2018-07-31
Waddell & Reed New Concepts A 663231 0.53% -50760 -7.11% 2017-12-31
iShares Nasdaq Biotechnology 1419614 1.10% -2703 -0.19% 2018-09-12
Vanguard Extended Market Idx Inv 1300930 1.04% 13500 1.05% 2018-07-31
VA CollegeAmerica Smcap World 529E 1057000 0.85% -2546000 -70.66% 2018-06-30
iShares Russell 2000 Growth 967441 0.75% -933 -0.10% 2018-09-12
Waddell & Reed Accumulative A 420000 0.34% -- -- 2017-12-31
CREF Stock R1 691905 0.55% 309079 80.74% 2018-07-31
BlackRock Health Sciences Opps Inv A 655400 0.52% -- -- 2018-07-31
JNL/Oppenheimer Global Growth B 555080 0.44% 4010 0.73% 2018-06-30
Janus Venture D 579062 0.46% 29774 5.42% 2018-03-31
Janus Triton D 1760332 1.41% 186453 11.85% 2018-03-31
Goldman Sachs Small/Mid Cap Growth A 563844 0.45% -10562 -1.84% 2018-03-31
VA CollegeAmerica Grth Fund of Amer 529F 1260000 1.01% -- -- 2018-03-31
Franklin Biotechnology Discovery A 970200 0.78% -46800 -4.60% 2018-03-31
Invesco Small Cap Growth A 661118 0.53% -- -- 2017-12-31
AZ InvestEd Ivy Mid Cap Growth E 935527 0.75% -99940 -9.65% 2017-12-31
T. Rowe Price New Horizons 1620149 1.34% -104851 -6.08% 2016-09-30
T. Rowe Price Health Sciences 1744257 1.44% -599800 -25.59% 2016-12-31
Prudential Jennison Health Sciences A 1092382 0.90% -324486 -22.90% 2016-12-31
Fidelity® Puritan® Fund 801800 0.80% -- -- 2015-09-30
Janus Triton Fund 1045153 1.00% -- -- 2015-09-30
iShares Russell 2000 (AU) 1263205 1.30% -1590 -0.10% 2015-11-19
VA CollegeAmerica Small Cap World 1381000 1.40% -27000 -1.90% 2015-09-30
Fidelity® Growth Company Fund 2811550 2.80% -23700 -0.80% 2015-09-30
Fidelity® Select Biotechnology Portfolio 4559264 4.50% 2800 0.10% 2015-09-30

Julian Charles Baker Mr. Julian C. Baker is a Lead Independent Director at Genomic Health, Inc., Incyte Corp., a Co-Managing Member at Baker Bros. Advisors LP, a Managing Member at Baker Bros. Advisors GP LLC and a Partner at FBB Associates. He is on the Board of Directors at ACADIA Pharmaceuticals, Inc., Genomic Health, Inc. and Incyte Corp. Mr. Baker was previously employed as an Independent Director by Idera Pharmaceuticals, Inc., a Member by Credit Suisse First Boston Corp., a Principal by CSFB Private Equity Partners LLC, and an Advisory Board Member by Elm Street Venture Advisors, Inc. He also served on the board at Trimeris, Inc., Neurogen Corp., Theravance, Inc. and Presidio Pharmaceuticals, Inc. He received his undergraduate degree from Harvard University.
Edmund P. Harrigan Edmund P. Harrigan is on the board of ACADIA Pharmaceuticals, Inc. and 4 other companies. In his past career he was VP & Head-Neuroscience & Ophthalmology at Pfizer Inc. Dr. Harrigan received an undergraduate degree from St. Anselm College and a doctorate from the University of Massachusetts Medical School.
Daniel B. Soland Mr. Daniel B. Soland is an Independent Director at KalVista Pharmaceuticals, Inc., an Independent Director at ACADIA Pharmaceuticals, Inc. and an Independent Director at DBV Technologies SA. He is on the Board of Directors at KalVista Pharmaceuticals, Inc., ACADIA Pharmaceuticals, Inc. and DBV Technologies SA. Mr. Soland was previously employed as a Chief Executive Officer & Executive Director by uniQure NV, a Non-Executive Director by Oxford Biomedica Plc, a Chief Operating Officer & Senior Vice President by Shire ViroPharma, Inc., a President by Chiron Vaccines Ltd., a President-Chiron Vaccines by Chiron Corp., a President & Chief Executive Officer by TEKNON PHARMACEUTICALS INC, a Director-Worldwide Marketing Operations & VP by Corixa Corp., and a VP & Director-Worldwide Marketing Operations by GlaxoSmithKline Plc. He also served on the board at Tarsa Therapeutics, Inc. He received his undergraduate degree from the University of Iowa.
Srdjan R. Stankovic Currently, Srdjan R. Stankovic occupies the position of President of ACADIA Pharmaceuticals, Inc. He is also on the board of Neurogene, Inc. In the past Dr. Stankovic held the position of SVP-Clinical Development & Medical Affairs at Alkermes Plc, Vice President-US Clinical Development at UCB Pharma, Inc., Vice President-US Clinical Development at Johnson & Johnson Pharmaceutical Research & Development LLC, Vice President-Worldwide Clinical Research at Cephalon, Inc., SVP & Head-Global Clinical Development at Teva Pharmaceuticals USA, Inc., Chief Development Officer & EVP at Neurogen Corp. and SVP-Medical Affairs & Clinical Development at Forest Laboratories, Inc. Srdjan R. Stankovic received a doctorate from the University of Belgrade and a graduate degree from The University of Alabama.
Stephen R. Davis Presently, Stephen R. Davis holds the position of Chief Executive Officer & Director at ACADIA Pharmaceuticals, Inc. Mr. Davis is also on the board of Bellicum Pharmaceuticals, Inc. In his past career Mr. Davis occupied the position of Chief Operating Officer, Director & EVP at Heron Therapeutics, Inc., Attorney-Corporate & Securities at Milbank, Tweed, Hadley & McCloy LLP, President, CEO, CFO, COO & Secretary at Neurogen Corp. and Chief Operating Officer & Executive Vice President at Ardea Biosciences, Inc. Mr. Davis received an undergraduate degree from Southern Nazarene University and a graduate degree from Vanderbilt Law School.
Daniel B. Soland Mr. Daniel B. Soland is an Independent Director at KalVista Pharmaceuticals, Inc., an Independent Director at ACADIA Pharmaceuticals, Inc. and an Independent Director at DBV Technologies SA. He is on the Board of Directors at KalVista Pharmaceuticals, Inc., ACADIA Pharmaceuticals, Inc. and DBV Technologies SA. Mr. Soland was previously employed as a Chief Executive Officer & Executive Director by uniQure NV, a Non-Executive Director by Oxford Biomedica Plc, a Chief Operating Officer & Senior Vice President by Shire ViroPharma, Inc., a President by Chiron Vaccines Ltd., a President-Chiron Vaccines by Chiron Corp., a President & Chief Executive Officer by TEKNON PHARMACEUTICALS INC, a Director-Worldwide Marketing Operations & VP by Corixa Corp., and a VP & Director-Worldwide Marketing Operations by GlaxoSmithKline Plc. He also served on the board at Tarsa Therapeutics, Inc. He received his undergraduate degree from the University of Iowa.
Eliseo Oreste Salinas Eliseo Oreste Salinas is President-Research & Development at Phoenixus AG, President-Research & Development at Turing Pharmaceuticals LLC (a subsidiary of Phoenixus AG) and Chief Scientific Officer & Senior Vice President at ACADIA Pharmaceuticals, Inc. He is also on the board of ViroChem Pharma, Inc. and Fortuna Fix Ltd. In his past career he held the position of President & Chief Scientific Officer at Relmada Therapeutics, Inc. President & Chief Scientific Officer at Camp Nine, Inc. and President & Chief Scientific Officer at Relmada Therapeutics, Inc. (both are subsidiaries of Relmada Therapeutics, Inc.), Chief Medical Officer at New World Laboratories, Chief Medical Officer & Executive Vice President at Elan Corp. Plc, Chief Scientific Officer at Shire Plc, Chief Medical Officer, SVP-Research & Development at Adolor Corp., Executive VP, Head-Research & Development at StemCells, Inc., Chief Medical Officer & Head-Development at Elan Pharmaceuticals, Inc., VP-Regional Clinical Research & Development at Wyeth Research, Vice President-Research at Wyeth-Ayerst Research, Chief Scientific Officer of Shire Acquisition, Inc., Vice President & Head-CNS Product Development at Wyeth Corp. and Manager-International Project at Synth�0�1�0�8labo SA. Dr. Salinas received a doctorate from Universidad de Buenos Aires and a graduate degree from Universit�0�1�0�8 Pierre et Marie Curie.
Laura A. Brege Ms. Laura A. Brege is an Independent Director at Dynavax Technologies Corp., an Independent Director at Portola Pharmaceuticals, Inc., an Independent Director at Pacira Biosciences, Inc., an Independent Director at ACADIA Pharmaceuticals, Inc., a Chairman Elect at Council on International Educational Exchange, Inc. and an Independent Director at HLS Therapeutics, Inc. She is on the Board of Directors at Mirum Pharmaceuticals, Inc., Dynavax Technologies Corp., Portola Pharmaceuticals, Inc., Pacira Biosciences, Inc., ACADIA Pharmaceuticals, Inc., Ohio University Foundation and HLS Therapeutics, Inc. Ms. Brege was previously employed as a Managing Director by Cervantes Life Science Partners LLC, an Independent Director by Aratana Therapeutics, Inc., a President, Chief Executive Officer & Director by Nodality, Inc., an Independent Director by Delcath Systems, Inc., a General Partner by Red Rock Capital Management, Inc., a COO, Chief Business Officer & Executive VP by Onyx Pharmaceuticals, Inc., a Chief Financial Officer & Senior Vice President by COR Therapeutics, Inc., a Chief Financial Officer & Vice President by Flextronics Corp., a Treasurer & Vice President by The Cooper Cos., Inc., and an Independent Director by The Bay Area Bioscience Association. She also served on the board at Angiotech Pharmaceuticals, Inc., Avexus, Inc. and Zvents, Inc. She received her undergraduate degree from The Ohio University and an MBA from The University of Chicago.
Stephen R. Biggar Presently, Stephen R. Biggar is Chairman at ACADIA Pharmaceuticals, Inc. and Partner at Baker Bros. Advisors LP. He is also on the board of Kiniksa Pharmaceuticals Ltd. and Vivelix Pharmaceuticals, Ltd. Dr. Biggar received a doctorate from Stanford University and an undergraduate degree from the University of Rochester.
Elena H. Ridloff Presently, Elena H. Ridloff occupies the position of Chief Financial Officer & Executive Vice President of ACADIA Pharmaceuticals, Inc. In the past she was Senior Analyst at Maverick Capital Ltd., Vice President-Investor Relations at Alexion Pharmaceuticals, Inc., Chief Executive Officer & Managing Member at BioVision, Inc. and Senior Analyst at Paramount BioCapital Asset Management, Inc. She received an undergraduate degree from the University of Pennsylvania.
Austin D. Kim Currently, Austin D. Kim occupies the position of Secretary, Executive VP & General Counsel at ACADIA Pharmaceuticals, Inc. In his past career he held the position of Vice President & Deputy General Counsel at Teva Pharmaceutical Industries Ltd. Secretary & Director at Auspex Pharmaceuticals, Inc. Secretary of NuPathe, Inc. Secretary of Cephalon, Inc. and Deputy General Counsel at IVAX LLC (which are all subsidiaries of Teva Pharmaceutical Industries Ltd.). Mr. Kim received an undergraduate degree from Stanford University and a graduate degree from Columbia Law School.
Laura A. Brege Ms. Laura A. Brege is an Independent Director at Dynavax Technologies Corp., an Independent Director at Portola Pharmaceuticals, Inc., an Independent Director at Pacira Biosciences, Inc., an Independent Director at ACADIA Pharmaceuticals, Inc., a Chairman Elect at Council on International Educational Exchange, Inc. and an Independent Director at HLS Therapeutics, Inc. She is on the Board of Directors at Mirum Pharmaceuticals, Inc., Dynavax Technologies Corp., Portola Pharmaceuticals, Inc., Pacira Biosciences, Inc., ACADIA Pharmaceuticals, Inc., Ohio University Foundation and HLS Therapeutics, Inc. Ms. Brege was previously employed as a Managing Director by Cervantes Life Science Partners LLC, an Independent Director by Aratana Therapeutics, Inc., a President, Chief Executive Officer & Director by Nodality, Inc., an Independent Director by Delcath Systems, Inc., a General Partner by Red Rock Capital Management, Inc., a COO, Chief Business Officer & Executive VP by Onyx Pharmaceuticals, Inc., a Chief Financial Officer & Senior Vice President by COR Therapeutics, Inc., a Chief Financial Officer & Vice President by Flextronics Corp., a Treasurer & Vice President by The Cooper Cos., Inc., and an Independent Director by The Bay Area Bioscience Association. She also served on the board at Angiotech Pharmaceuticals, Inc., Avexus, Inc. and Zvents, Inc. She received her undergraduate degree from The Ohio University and an MBA from The University of Chicago.
Laura A. Brege Ms. Laura A. Brege is an Independent Director at Dynavax Technologies Corp., an Independent Director at Portola Pharmaceuticals, Inc., an Independent Director at Pacira Biosciences, Inc., an Independent Director at ACADIA Pharmaceuticals, Inc., a Chairman Elect at Council on International Educational Exchange, Inc. and an Independent Director at HLS Therapeutics, Inc. She is on the Board of Directors at Mirum Pharmaceuticals, Inc., Dynavax Technologies Corp., Portola Pharmaceuticals, Inc., Pacira Biosciences, Inc., ACADIA Pharmaceuticals, Inc., Ohio University Foundation and HLS Therapeutics, Inc. Ms. Brege was previously employed as a Managing Director by Cervantes Life Science Partners LLC, an Independent Director by Aratana Therapeutics, Inc., a President, Chief Executive Officer & Director by Nodality, Inc., an Independent Director by Delcath Systems, Inc., a General Partner by Red Rock Capital Management, Inc., a COO, Chief Business Officer & Executive VP by Onyx Pharmaceuticals, Inc., a Chief Financial Officer & Senior Vice President by COR Therapeutics, Inc., a Chief Financial Officer & Vice President by Flextronics Corp., a Treasurer & Vice President by The Cooper Cos., Inc., and an Independent Director by The Bay Area Bioscience Association. She also served on the board at Angiotech Pharmaceuticals, Inc., Avexus, Inc. and Zvents, Inc. She received her undergraduate degree from The Ohio University and an MBA from The University of Chicago.
James M. Daly James M. Daly is on the board of ACADIA Pharmaceuticals, Inc. and 6 other companies. In the past Mr. Daly held the position of Chief Commercial Officer & Executive VP at Incyte Corp., Principal at Francis Cauffman, Inc., SVP-Global Marketing & Commercial Development at Amgen, Inc. and Senior Vice President of Amgen Ventures LLC (a subsidiary of Amgen, Inc.) and SVP, General Manager-Respiratory & Anti Infectives at GlaxoSmithKline LLC. He received an MBA from The State University of New York and an MBA and an undergraduate degree from State University of New York at Buffalo.
James M. Daly James M. Daly is on the board of ACADIA Pharmaceuticals, Inc. and 6 other companies. In the past Mr. Daly held the position of Chief Commercial Officer & Executive VP at Incyte Corp., Principal at Francis Cauffman, Inc., SVP-Global Marketing & Commercial Development at Amgen, Inc. and Senior Vice President of Amgen Ventures LLC (a subsidiary of Amgen, Inc.) and SVP, General Manager-Respiratory & Anti Infectives at GlaxoSmithKline LLC. He received an MBA from The State University of New York and an MBA and an undergraduate degree from State University of New York at Buffalo.
Randall Owen Presently, Randall Owen holds the position of Chief Medical Officer & SVP-Clinical Development at ACADIA Pharmaceuticals, Inc. Dr. Owen previously was Group Director-Global Clinical Research at Bristol-Myers Squibb Co. and Vice President-US Clinical Affairs at Lundbeck LLC. He received an undergraduate degree from Haverford College and a doctorate from East Tennessee State University.
Robert Kaper Robert Kaper is Senior VP & Global Head-Medical Affairs at ACADIA Pharmaceuticals, Inc. In the past he was Senior Vice President-Medical & Scientific Affairs at AMAG Pharmaceuticals, Inc. and Vice President-Global Medical Affairs at Teva Pharmaceuticals Ltd. Dr. Kaper received a doctorate from Vrije Universiteit Amsterdam.
Daniel B. Soland Mr. Daniel B. Soland is an Independent Director at KalVista Pharmaceuticals, Inc., an Independent Director at ACADIA Pharmaceuticals, Inc. and an Independent Director at DBV Technologies SA. He is on the Board of Directors at KalVista Pharmaceuticals, Inc., ACADIA Pharmaceuticals, Inc. and DBV Technologies SA. Mr. Soland was previously employed as a Chief Executive Officer & Executive Director by uniQure NV, a Non-Executive Director by Oxford Biomedica Plc, a Chief Operating Officer & Senior Vice President by Shire ViroPharma, Inc., a President by Chiron Vaccines Ltd., a President-Chiron Vaccines by Chiron Corp., a President & Chief Executive Officer by TEKNON PHARMACEUTICALS INC, a Director-Worldwide Marketing Operations & VP by Corixa Corp., and a VP & Director-Worldwide Marketing Operations by GlaxoSmithKline Plc. He also served on the board at Tarsa Therapeutics, Inc. He received his undergraduate degree from the University of Iowa.
Bob Mischler Bob Mischler is Senior VP-Strategy & Technology Operations at ACADIA Pharmaceuticals, Inc. In the past he was Vice President-Scientific Affairs at Ardea Biosciences, Inc. He received an undergraduate degree from Indiana University and an MBA from UCLA Anderson School of Management.
Bob Mischler Bob Mischler is Senior VP-Strategy & Technology Operations at ACADIA Pharmaceuticals, Inc. In the past he was Vice President-Scientific Affairs at Ardea Biosciences, Inc. He received an undergraduate degree from Indiana University and an MBA from UCLA Anderson School of Management.
James M. Daly James M. Daly is on the board of ACADIA Pharmaceuticals, Inc. and 6 other companies. In the past Mr. Daly held the position of Chief Commercial Officer & Executive VP at Incyte Corp., Principal at Francis Cauffman, Inc., SVP-Global Marketing & Commercial Development at Amgen, Inc. and Senior Vice President of Amgen Ventures LLC (a subsidiary of Amgen, Inc.) and SVP, General Manager-Respiratory & Anti Infectives at GlaxoSmithKline LLC. He received an MBA from The State University of New York and an MBA and an undergraduate degree from State University of New York at Buffalo.
James M. Daly James M. Daly is on the board of ACADIA Pharmaceuticals, Inc. and 6 other companies. In the past Mr. Daly held the position of Chief Commercial Officer & Executive VP at Incyte Corp., Principal at Francis Cauffman, Inc., SVP-Global Marketing & Commercial Development at Amgen, Inc. and Senior Vice President of Amgen Ventures LLC (a subsidiary of Amgen, Inc.) and SVP, General Manager-Respiratory & Anti Infectives at GlaxoSmithKline LLC. He received an MBA from The State University of New York and an MBA and an undergraduate degree from State University of New York at Buffalo.
James M. Daly James M. Daly is on the board of ACADIA Pharmaceuticals, Inc. and 6 other companies. In the past Mr. Daly held the position of Chief Commercial Officer & Executive VP at Incyte Corp., Principal at Francis Cauffman, Inc., SVP-Global Marketing & Commercial Development at Amgen, Inc. and Senior Vice President of Amgen Ventures LLC (a subsidiary of Amgen, Inc.) and SVP, General Manager-Respiratory & Anti Infectives at GlaxoSmithKline LLC. He received an MBA from The State University of New York and an MBA and an undergraduate degree from State University of New York at Buffalo.
James M. Daly James M. Daly is on the board of ACADIA Pharmaceuticals, Inc. and 6 other companies. In the past Mr. Daly held the position of Chief Commercial Officer & Executive VP at Incyte Corp., Principal at Francis Cauffman, Inc., SVP-Global Marketing & Commercial Development at Amgen, Inc. and Senior Vice President of Amgen Ventures LLC (a subsidiary of Amgen, Inc.) and SVP, General Manager-Respiratory & Anti Infectives at GlaxoSmithKline LLC. He received an MBA from The State University of New York and an MBA and an undergraduate degree from State University of New York at Buffalo.
Michael J. Yang Michael J. Yang is Chief Commercial Officer & Executive VP at ACADIA Pharmaceuticals, Inc. In the past Mr. Yang occupied the position of President at Johnson & Johnson President at Janssen Biotech, Inc. and General Manager of Veridex LLC (both are subsidiaries of Johnson & Johnson), Vice President-Sales & Marketing for Ortho Biotech, Inc. and General Manager of Therakos, Inc. He received an undergraduate degree from San Diego State University.
Daryl DeKarske Currently, Daryl DeKarske occupies the position of Senior VP & Head-Global Regulatory Affairs at ACADIA Pharmaceuticals, Inc. Mr. DeKarske is also on the board of Screening for Mental Health, Inc. In the past he was VP & Head-Neurology, Ophthalmology & Oncology at Shire Plc. Daryl DeKarske received an undergraduate degree and a graduate degree from the University of Michigan.
Daryl DeKarske Mr. Daryl DeKarske is a Senior VP & Head-Global Regulatory Affairs at ACADIA Pharmaceuticals, Inc. He is on the Board of Directors at Screening for Mental Health, Inc. Mr. DeKarske was previously employed as a Vice President by Shire Plc. He received his undergraduate degree from the University of Michigan and a graduate degree from the University of Michigan.
Eric Miller Presently, Eric Miller holds the position of Principal Accounting Officer & Senior Director at ACADIA Pharmaceuticals, Inc. He received an undergraduate degree from Carnegie Mellon University.
Charmaine Lykins Charmaine Lykins occupies the position of Senior Vice President-Marketing of ACADIA Pharmaceuticals, Inc. Ms. Lykins received an MBA from the University of South Carolina and an undergraduate degree from Ball State University (Indiana).

量化对比

全部评论 2

  • 【美股盘前消息速报】①美国股指期货周一盘前走强,上月强劲的非农数据表明美国经济复苏远超预期,人们对美国经济重启的信心增强。②截至发稿,道指期货涨0.7%,标普500期指涨0.5%,纳指期货涨0.4%。③英国富时100指数涨0.9%,德国DAX指数涨1.1%,法国CAC-40指数涨1.2%。④美债收益率上浮逾1个基点至1.732%。⑤美元指数下挫0.05%至92.97。⑥ 现货黄金下跌0.24%至1724.71美元/盎司。⑦ 美国劳工部上周五公布的数据显示,美国3月非农就业岗位增加91.6万个,为去年8月以来最大增幅。⑧分析指出,美联储将不得不比官员们目前预期的时点更早加息,即便他们对通胀采用了新的观望策略。⑨本周最值得关注的宏观事件包括周三的3月16日至17日美国联邦公开市场委员会(FOMC)会议纪要以及美联储主席鲍威尔讲话。⑩激光雷达概念股盘前走高,Velodyne涨5.2%,维视图像涨3.2%,Luminar涨2.3%。⑪半导体板块盘前走强,恩智浦半导体涨超3%,台积电涨超2%,美光科技涨超1%。⑫Archegos爆仓概念股盘前小幅走高,爱奇艺涨2%,跟谁学涨近2%,探索频道A涨近1%,VIACOMCBS涨0.58%。⑬生物技术板块盘前下挫,克利夫兰生物实验室跌超18%,Eloxx Pharmaceuticals跌近9%,Hepion Pharmaceuticals跌超6%。⑭区块链板块盘前走弱,Riot Blockchain、第九城市跌超3%,Marathon Digital、迅雷跌超2%。⑮特斯拉盘前涨8%。第一季度交付量超预期,多家投行上调目标价。⑯游戏驿站盘前跌幅扩大至16%,此前公司宣布将最多配售350万股股份,募资最多10亿美元。⑰药企阿卡迪亚盘前跌14%,不久前FDA拒绝了该公司将其药物Nuplazid治疗范围扩大至痴呆症引发的幻觉的申请。⑱桑普拉能源将向KKR集团以33.7亿美元价格出售其基础设施部门。⑲500彩票网宣布收购一家7nm矿机生产商。500彩票网盘前异动,现涨6.7%。

  • 药企阿卡迪亚盘前跌14%,不久前FDA拒绝了该公司将其药物Nuplazid治疗范围扩大至痴呆症引发的幻觉的申请。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐